Psychemedics 10Q 2023 Q1 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
	For the quarterly period ended March 31, 2023
	or
☐	Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
	for the transition period from _________ to __________

Commission file number: 1-13738

PSYCHEMEDICS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware		58-1701987
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

289 Great Road
Acton, MA		01720
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number including area code: (978) 206-8220

Securities registered pursuant to section 12(b) of the act:

Title of Class	Trading Symbol(s)	Name of each exchange on which registered
Common stock. $0.005 par value	PMD	The Nasdaq Stock Market, LLC.

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See Rule 12b-2 of the Exchange Act.

	Large accelerated filer	☐
	Accelerated filer	☐
	Non–accelerated filer	☒
	Smaller reporting company	☒
	Emerging growth company	☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of Common Stock of the Registrant, par value $0.005 per share, outstanding at May 8, 2023 was 5,721,147.

PSYCHEMEDICS CORPORATION

FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2023

INDEX

PSYCHEMEDICS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value)

(UNAUDITED)

	March 31,			December 31,
	2023			2022

ASSETS
Current Assets:
Cash	$	4,380		$	4,750
Accounts receivable, net of allowance for doubtful accounts of $73 at March 31, 2023, and $87 at December 31, 2022		4,058			3,739
Prepaid expenses and other current assets		1,088			1,136
Income tax receivable		9			339

Total Current Assets		9,535			9,964

Fixed assets, net of accumulated amortization and depreciation of $22,428 at March 31, 2023, and $21,964 at December 31, 2022		4,150			4,573
Other assets		840			823
Net deferred tax assets		850			691
Operating lease right-of-use assets		2,532			2,681

Total Assets	$	17,907		$	18,732

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities:
Accounts payable	$	785		$	448
Accrued expenses		3,632			3,939
Current portion of long-term debt		297			294
Current portion of operating lease liabilities		1,076			1,037

Total Current Liabilities		5,790			5,718

Long-term debt		230			305
Long-term portion of operating lease liabilities		1,721			1,938
Total Liabilities		7,741			7,961

Commitments and Contingencies (Note 5)

Shareholders' Equity:
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding
Common stock, $0.005 par value; 50,000 shares authorized; 6,354 and 6,349 shares issued and 5,686 and 5,681 shares outstanding, respectively		32			32
Additional paid-in capital		34,452			34,275
Accumulated deficit		(12,602	)		(11,820	)
Less - Treasury stock, at cost, 668 shares		(10,082	)		(10,082	)
Accumulated other comprehensive loss		(1,634	)		(1,634	)

Total Shareholders' Equity		10,166			10,771

Total Liabilities and Shareholders' Equity	$	17,907		$	18,732

See accompanying notes to condensed consolidated financial statements.

PSYCHEMEDICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(UNAUDITED)

	Three Months Ended
	March 31,
	2023			2022

Revenues	$	5,859		$	6,508
Cost of revenues		3,654			4,067

Gross profit		2,205			2,441

Operating Expenses:
General & administrative		1,646			1,327
Marketing & selling		789			806
Research & development		298			318

Total Operating Expenses		2,733			2,451

Operating loss		(528	)		(10	)
Other (expense) income, net		(5	)		66

(Loss) income before (benefit from) provision for income taxes		(533	)		56

(Benefit from) provision for income taxes		(149	)		17

Net (loss) income	$	(384	)	$	39

Basic net (loss) income per share	$	(0.07	)	$	0.01

Diluted net (loss) income per share	$	(0.07	)	$	0.01

Dividends declared per share	$	0.07		$	-

See accompanying notes to condensed consolidated financial statements.

PSYCHEMEDICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands, except per share amounts)

(UNAUDITED)

	Common Stock, $0.005 par value				Additional
	Common Shares		Common		Paid-In		Treasury Stock					Accumulated			Accumulated Other
	Outstanding		Stock		Capital		Shares		Cost			Deficit			Comprehensive Loss			Total
BALANCE, December 31, 2022		6,349	$	32	$	34,275		668	$	( 10,082	)	$	( 11,820	)	$	( 1,634	)	$	10,771
Shares issued – vested		5		-		-		-		-			-			-			-
Stock compensation expense		-		-		177		-		-			-			-			177
Cash dividends declared ($0.07 per share)		-		-		-		-		-			( 398	)		-			( 398	)
Net loss		-		-		-		-		-			( 384	)		-			( 384	)
BALANCE, March 31, 2023		6,354	$	32	$	34,452		668	$	( 10,082	)	$	( 12,602	)	$	( 1,634	)	$	10,166

BALANCE, December 31, 2021		6,257	$	31	$	33,478		668	$	( 10,082	)	$	( 9,550	)	$	( 1,634	)	$	12,243
Shares issued – vested		2		-		-		-		-			-			-			-
Stock compensation expense		-		-		179		-		-			-			-			179
Net income		-		-		-		-		-			39			-			39
BALANCE, March 31, 2022		6,259	$	31	$	33,657		668	$	( 10,082	)	$	( 9,511	)	$	( 1,634	)	$	12,461

See accompanying notes to condensed consolidated financial statements.

PSYCHEMEDICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(UNAUDITED)

	Three Months Ended
	March 31,
	2023			2022

CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$	(384	)	$	39
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization		479			628
ROU asset amortization		235			232
Stock-based compensation		177			179
Changes in operating assets and liabilities:
Accounts receivable		(319	)		(588	)
Prepaid expenses and other current assets		48			466
Income tax receivable		330			17
Net deferred tax asset		(159	)		-
Accounts payable		337			(272	)
Operating lease liabilities		(264	)		(213	)
Accrued expenses		(705	)		(143	)
Net cash (used in) provided by operating activities		(225	)		345

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment and leasehold improvements		(20	)		(10	)
Cost of internally developed software		(21	)		(33	)
Other assets		(32	)		7
Net cash used in investing activities		(73	)		(36	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of equipment financing		(72	)		(174	)
Net cash used in financing activities		(72	)		(174	)

Net (decrease) increase in cash		(370	)		135
Cash, beginning of period		4,750			1,992
Cash, end of period	$	4,380		$	2,127

Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	5		$	10
Cash paid for operating leases	$	291		$	269
Right-of-use assets acquired through operating leases	$	86		$	-

See accompanying notes to condensed consolidated financial statements.

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.	Basis of Presentation

The interim condensed consolidated financial statements of Psychemedics Corporation (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all the information and note disclosures required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2022, included in the Company's 2022 Annual Report on Form 10-K (“10-K”), as filed with the SEC.

The accompanying condensed consolidated financial statements are unaudited but, in the opinion of management, include all adjustments necessary for a fair presentation of results for these interim periods. The condensed consolidated balance sheet as of December 31, 2022, has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm, but does not include all the information and footnotes required for complete annual financial statements. The Company’s comprehensive (loss)/income is equal to its net (loss)/income for all periods presented.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended March 31, 2023, may not be indicative of the results that may be expected for the year ending December 31, 2023, or any other period.

Unless the context requires otherwise, the terms “we”, “us”, “our”, or “the Company” refer to Psychemedics Corporation and its wholly-owned consolidated subsidiaries.

2.	Financial Information

Liquidity and Management’s Plans

At March 31, 2023, the Company’s principal sources of liquidity included approximately $4.4 million of cash. Management currently believes that such funds, together with future operating profits, should be adequate to fund anticipated working capital requirements, including equipment financing obligations, and capital expenditures for at least the next 12 months. Depending upon the Company’s results of operations, its future capital needs and available marketing opportunities, the Company may use various financing sources to raise additional funds. Such sources could include but are not limited to, issuance of common stock, debt financing, lines of credit, or equipment leasing, although there is no assurance that such financings will be available to the Company on terms it deems acceptable, if at all.

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

2.	Financial Information (continued)

Accounts Receivable

The Company believes its allowance for credit losses related to its accounts receivable remained adequate as of March 31, 2023, due to the essential nature of its customers business, as well as the diversity of its large customer base. While the Company anticipates there could be an increase in the aging of its accounts receivable, the Company does not anticipate a significant increase in default risk.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial instruments. The Company has adopted ASU 2016-13 in the first quarter of 2023 utilizing the modified retrospective transition method. Based on the composition of the Company’s investment portfolio, current market conditions, and historical credit loss activity, the adoption of ASU 2016-13 does not have a material impact on the consolidated financial statements.

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

3.	Stock-Based Compensation

The Company’s 2006 Incentive Plan (“the Plan”) provides for cash-based awards or the grant or issuance of stock-based awards. As of March 31, 2023, 321 thousand shares remained available for future grant under the Plan.

Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). The compensation cost charged against income is included in cost of revenues and operating expenses as follows (in thousands):

	Three Months Ended
	March 31,
	2023		2022
Stock-based compensation related to:
Stock option grants	$	20	$	53
Stock unit awards		157		126
Total stock-based compensation	$	177	$	179

There was no income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation arrangements for the three ended March 31, 2023, and 2022.

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

3.	Stock-Based Compensation (continued)

A summary of the Company’s stock option activity for the three months ended March 31, 2023, is as follows (in thousands except per share amounts and years):

						Weighted Average
				Weighted Average		Remaining		Aggregate
	Number of			Exercise Price		Contractual Life		Intrinsic
	Shares			Per Share		(years)		Value⁽¹⁾
Outstanding, December 31, 2022		508		$	14.19		5.1	$	25
Canceled		( 64	)	$	14.70
Outstanding, March 31, 2023		444		$	14.09		4.8	$	33

Exercisable, March 31, 2023		402		$	14.67		4.6	$	17

(1)

Intrinsic value is calculated based on the amount by which the closing market value of the Company’s stock exceeded the exercise price of the underlying options, multiplied by the number of shares.

A summary of the Company’s stock unit award (“SUA”) activity for the three months ended March 31, 2023, is as follows (in thousands except per share amounts):

	Number of Shares			Weighted Average Grant-Date Fair Value Per Share

Outstanding & Unvested, December 31, 2022		238		$	6.10
Converted to common stock		(5	)	$	6.36
Cancelled		(2	)	$	6.19
Forfeited		(9	)	$	5.90
Outstanding & Unvested, March 31, 2023		222		$	6.10

As of March 31, 2023, 912 thousand shares of common stock were reserved for issuance under the Plan. As of March 31, 2023, the unamortized fair value of awards relating to outstanding SUAs and options was $941 thousand, which is expected to be amortized over a weighted average period of 2.2 years.

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

4.	Basic and Diluted Net (Loss)/Income Per Share

Basic net (loss)/income per share is computed by dividing net (loss)/income by the weighted average number of common shares outstanding during the period. Diluted net (loss)/income per share is computed by dividing net (loss)/income by the weighted average number of common and dilutive common equivalent shares outstanding during the period when the effect is dilutive. The number of dilutive common equivalent shares outstanding during the period was determined in accordance with the treasury-stock method. Common equivalent shares consisted of common stock issuable upon the exercise of outstanding options and common stock issuable upon the vesting of outstanding, unvested SUAs. Basic and diluted weighted average common shares outstanding for the three months ended March 31, 2023, and 2022 were as follows (in thousands):

	Three Months Ended
	March 31,
	2023		2022
Weighted average common shares outstanding, basic		5,685		5,590
Dilutive common equivalent shares		-		56
Weighted average common shares outstanding, diluted		5,685		5,646

The computation of diluted earnings per share for the three months ended March 31, 2023, and 2022 excludes the effect of the potential exercise of stock awards, including stock options, when the effect is anti-dilutive. For the three months ended March 31, 2023, and 2022, the number of antidilutive stock awards excluded from diluted earnings per share were 620 thousand and 545 thousand, respectively.

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

5.	Commitments and Contingencies

From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. The Company continuously assesses the potential liability related to the Company’s pending litigation and revises its estimates when additional information becomes available. Although it is difficult to predict the ultimate outcome of these cases, management believes, that any ultimate liability would not have a material adverse effect on the consolidated statements of operations. However, an unforeseen unfavorable development in any of these cases could have a material adverse effect on the statements of operations or cash flows in the period in which it is recorded. Developments in legal proceedings and other matters that could cause changes in the amounts previously accrued are evaluated each reporting period.

Settlements

As previously reported in the 10-K, on December 6, 2021, the Company entered into a binding Memorandum of Understanding to settle a purported class action lawsuit related to certain California wage and hour laws. The lawsuit, Enma Sagastume v. Psychemedics Corporation, Case No. 2:20-CV-06624-DSF, is pending in the United States District Court for the Central District of California (the “California Lawsuit”) and is similar to numerous lawsuits filed against employers with operations in California.

The Company has accrued $1.2 million as of March 31, 2023 related to the California Lawsuit, which is included in accrued expenses on the accompanying consolidated balance sheets.

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

6.	Operating Leases

The Company has five operating leases for office and laboratory space used to conduct business. The exercise of lease renewal options is at our discretion. There is one lease which contains renewal options to extend the lease terms included in our Right-Of-Use (“ROU”) assets and lease liabilities as they are reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain of exercise. As most of the Company’s leases do not provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at the lease commencement date in determining the net present value (NPV) of the lease payments.

As of March 31, 2023, the Company recognized a Right-Of-Use (“ROU”) asset of $2.5 million and an operating lease liability of $2.8 million based on the present value of the minimum rental payments. The weighted average discount rate used for leases as of March 31, 2023, is 3.9%. The weighted average lease term as of March 31, 2023, is 2.9 years. The operating lease expense for the three months ended March 31, 2023, was $262 thousand.

Maturities and balance sheet presentation of the Company’s lease liabilities for all operating leases as of March 31, 2023, is as follows (in thousands):

April 1, 2023, through December 31, 2023	$	876
2024		1,106
2025		564
2026		460
Total lease payments		3,006
Less: interest		(209	)
Present value of lease liabilities	$	2,797

Current operating lease liabilities	$	1,076
Long-term operating lease liabilities		1,721
	$	2,797

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

7.	Debt and Other Financing Arrangements

On March 20, 2014, the Company entered into an equipment financing arrangement (“Loan Agreement”) with Banc of America Leasing & Capital, which it amended on August 8, 2014, September 15, 2015, October 30, 2017, and December 2, 2019. The terms of the arrangement are detailed in the 10-K.

The weighted average interest rate on outstanding debt under the Loan Agreement was 3.8% for the three months ended March 31, 2023. The interest expense was $5 thousand for the three months ended March 31, 2023. As of March 31, 2023, the weighted average interest rate was 3.8% and there was $526 thousand of outstanding debt related under the Loan Agreement. The Company was in compliance with all loan covenants under the Loan Agreement as of March 31, 2023.

The annual principal repayment requirements for debt obligations as of March 31, 2023, were as follows (in thousands):

April 1, 2023, through December 31, 2023	$	222
2024		305
Long-term debt from equipment financing		527
Less: current portion of long-term debt from equipment financing		(297	)
Long-term debt from equipment financing, net of current portion	$	230

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

8.	Revenue

The table below disaggregates our external revenue by major source (in thousands):

	Three Months Ended
	March 31,
	2023		2022
Testing	$	4,938	$	5,724
Shipping/Collection (hair)		898		750
Other		23		34
Total Revenue	$	5,859	$	6,508

9.	Significant Customers

The Company had no customers that represented over 10% of revenue during either of the three-month periods ended March 31, 2023, or 2022. The Company had one customer that represented 16% and 17% of the total accounts receivable balance as of March 31, 2023, and 2022, respectively.

10.

Subsequent Events

On May 9, 2023, the Company declared a cash dividend of $0.07 per share, which will be paid on June 8, 2023, to shareholders of record on May 25, 2023.

Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FACTORS THAT MAY AFFECT FUTURE RESULTS

From time to time, information provided by the Company or statements made by its employees may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this report that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, cash flows, dividends, future business, growth opportunities, profitability, pricing, new accounts, customer base, market share, test volume, sales and marketing strategies, market demand for drug testing services in the U.S. and foreign drug testing laws and regulations, required investments in plant, equipment and people and new test development) may be “forward looking” statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the changes in U.S. and foreign government regulations, including but not limited to FDA regulations, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, the continued labor shortage, leveraging of its global operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, and general economic conditions. With respect to the continued payment of cash dividends, factors include, but are not limited to, all of the factors listed above plus cash flows, available surplus, capital expenditure reserves required, debt service obligations, regulatory requirements and other factors that the Board of Directors of the Company may take into account.

Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements represent the Company’s estimates and assumptions only as of the filing date of this Report. The Company expressly disclaim any duty to provide updates to forward-looking statements, and the estimates and assumptions associated with them, after the filing date of this Report, in order to reflect changes in circumstances or expectations, or the occurrence of unanticipated events, except to the extent required by applicable securities laws. All of the forward-looking statements are qualified in their entirety by reference to the factors discussed above and under “Risk Factors” set forth in Part I Item 1A of the 10-K, as well as the risks and uncertainties discussed elsewhere in this Report. The Company qualifies all of its forward-looking statements with these cautionary statements. The Company cautions you that these risks are not exhaustive. The Company operates in a continually changing business environment and new risks emerge from time to time.

OVERVIEW

Revenue for the first quarter of 2023 was $5.9 million compared to $6.5 million in the first quarter of 2022, a decrease of 10%. The Company reported net loss of $384 thousand, or ($0.07) per diluted share for the three months ended March 31, 2023, versus net income of $39 thousand, or $0.01 per diluted share for the same period in 2022. Revenue decrease for the quarter was primarily attributed to the continued labor shortage that impacts the Company’s customers. The Company declared a cash dividend of $0.07 per share to its shareholders during the three months ended March 31, 2023.

RESULTS OF OPERATIONS

Revenue decreased 10% for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to a decrease in domestic volumes. The Company’s domestic revenues were impacted by lower volumes from customers experiencing the effects of the continued labor shortage related to hiring.

Gross profit: The Company had a $2.2 million gross profit for the three months ended March 31, 2023, compared to a $2.4 million gross profit for the same period in 2022. Cost of revenues decreased by $0.4 million or 10% for the three months ended March 31, 2023, compared to the same period in 2022. Gross profit percentage remained at 38% for the three months ended March 31, 2023 and 2022.

General and administrative (“G&A”) expenses increased 24% or $0.3 million to $1.6 million for the three months ended March 31, 2023, compared to $1.3 million for the same period in 2022. As a percentage of revenue, G&A expenses were 28% and 20% for the three months ended March 31, 2023, and 2022, respectively. The increase in G&A expenses was driven by a combination of legal fees, personnel costs, accounting and consulting fees, and business insurance premiums.

Marketing and selling expenses remained flat at $0.8 million for the three months ended March 31, 2023, and 2022. Total marketing and selling expenses represented 13% and 12% of revenue for the three months ended March 31, 2023, and 2022, respectively.

Research and development (“R&D”) expenses remained flat at $0.3 million for the three months ended March 31, 2023, and 2022. R&D expenses represented 5% of revenue for the three months ended March 31, 2023, and 2022.

Provision for income taxes consisted primarily of federal and state income taxes in the United States. We estimate income taxes in each of the jurisdictions in which we operate. During the three months ended March 31, 2023, the Company recorded a tax benefit of $149 thousand (effective tax rate of 28%) and a tax provision of $17 thousand (effective tax rate of 30%) for the comparative period in 2022.

LIQUIDITY AND CAPITAL RESOURCES

At March 31, 2023, the Company had approximately $4.4 million of cash. The Company's operating activities used net cash of $0.2 million for the three months ended March 31, 2023. Investing activities used $0.1 million of net cash while financing activities used $0.1 million of net cash during the first three months of 2023.

Cash used in operating activities of $0.2 million reflected net loss of $0.4 million adjusted for depreciation and amortization of $0.5 million, ROU asset amortization of $0.2 million and stock-based compensation of $0.2 million. This was also impacted by an increase in operating assets of $0.1 million and a decrease in operating liabilities of $0.6 million.

Cash used in investing activities of $0.1 million is primarily related to internally developed software and equipment purchases. We anticipate spending less than $1.0 million in additional capital purchases for the remainder of 2023.

Cash used in financing activities of $0.1 million is solely related to payments on equipment financing.

Contractual obligations and other commercial commitments as of March 31, 2023, include legal commitments, operating lease commitments, and outstanding debt, described in Notes 5, 6, and 7, respectively of the Notes to Condensed Consolidated Financial Statements.

While management currently believes that its existing funds and cash flow from operations should be adequate to fund the Company’s business for at least the next 12 months, economic conditions could adversely affect the Company’s future operating results and cash flows. Depending upon the Company’s results of operations, its future capital needs and available marketing opportunities, the Company may use various financing sources to raise additional funds. Such sources could include but are not limited to, issuance of common stock or debt financing, lines of credit, or equipment leasing, although there is no assurance that such financings will be available to the Company on terms it deems acceptable, if at all.

Item 4.

Controls and Procedures

As of the end of the period covered by this report (the “evaluation date”) the Company’s management under the supervision and with the participation of the Company’s Chief Executive Officer and Controller performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act. Based upon that evaluation, the Chief Executive Officer and Controller concluded as of the evaluation date, that the Company’s disclosure controls and procedures were effective for ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that its disclosure controls and procedures were also effective to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including the Company’s principal executive and principal financial officers, to allow timely decisions regarding required disclosure.

There has been no significant change in the Company’s internal control over financial reporting during the most recent fiscal quarter that has materially affected or is reasonably likely to materially affect the Company’s internal control over financial reporting.

PART II OTHER INFORMATION

Item 1.

Legal Proceedings

Information pertaining to legal proceedings can be found in Item 1. Financial Statements and Supplementary Data – Note 5 “Commitments and Contingencies”.

Item 1A.

Risk Factors

Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2022, includes a discussion of our risk factors. There have been no material changes in the risk factors described in such report.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

There were no purchases of treasury stock in the first three months of 2023.

Item 6.

Exhibits

31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Psychemedics Corporation

Date: May 11, 2023	By:	/s/ Raymond C. Kubacki
	Raymond C. Kubacki
	Chairman and Chief Executive Officer
	(principal executive officer)

Date: May 11, 2023	By:	/s/ William B. Norris
	William B. Norris
	Controller
	(principal accounting officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

	Page
PART I - FINANCIAL INFORMATION

Item 1 - Financial Statements (unaudited)
Condensed Consolidated Balance Sheets	3
Condensed Consolidated Statements of Operations	4
Condensed Consolidated Statements of Shareholders’ Equity	5
Condensed Consolidated Statements of Cash Flows	6
Notes to Condensed Consolidated Financial Statements	7

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations	16
Factors that May Affect Future Results	16
Overview	17
Results of Operations	17
Liquidity and Capital Resources	18

Item 4 - Controls and Procedures	19

PART II - OTHER INFORMATION
Item 1 - Legal Proceedings	20
Item 1A - Risk Factors	20
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 6 - Exhibits	20

Signatures	21

Psychemedics (PMDI) 10-Q2023 Q1 Quarterly report

Content analysis